Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America
July 22 2022 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that its Senior
Vice President and Chief People Officer, Carla Poulson, has been
named one of Savoy Magazine’s 2022 Most Influential Black
Executives in Corporate America.
Carla Poulson, Chief People Officer of Mersana,
has been named as one of Savoy Magazine’s 2022 Most Influential
Black Executives in Corporate America.
“Since Carla joined Mersana’s leadership team at the start of
2021, she has played an integral role in guiding the growth and
culture of our organization while also advancing our diversity and
inclusion objectives,” said Anna Protopapas, Chief Executive
Officer at Mersana Therapeutics. “We have benefitted greatly from
Carla’s talent acquisition, people management and organizational
development skills, as evidenced by our recent inclusion in The
Boston Globe’s Top Places to Work in Massachusetts. This honor from
Savoy Magazine is incredibly well-deserved, and we congratulate her
on this latest achievement.”
Prior to joining Mersana, Ms. Poulson served as Chief Human
Resources Officer at Akcea Therapeutics before its acquisition by
Ionis Pharmaceuticals. Prior to joining Akcea, she held multiple
roles of increasing responsibility during a decade of great
organizational growth at Vertex Pharmaceuticals, most recently
serving as Vice President, Human Resources. Earlier in her career,
she also held senior human resources positions at Ahold
Corporation, Pepsi Bottling Group and ExxonMobil Corporation. Ms.
Poulson earned a Master’s in Human Resources & Industrial
Relations and a B.S. in Industrial and Organizational Psychology,
both from the University of Illinois Urbana-Champaign.
“I am honored to receive this recognition and believe it speaks
to the strong workplace environments that I have contributed to
over the course of my career,” said Ms. Poulson. “With the support
of our inclusive, patient-centric team at Mersana, I am excited by
the opportunity to further our growth and pursue our goal to bring
forward new treatments to address unmet needs in cancer.”
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a
single-arm registrational trial in patients with platinum-resistant
ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial
evaluating UpRi in combination with other ovarian cancer therapies.
Mersana’s earlier stage programs include XMT-1660, a Dolasynthen
ADC targeting B7-H4, and XMT-2056, a STING-agonist ADC developed
using the company’s Immunosynthen platform and targeting a novel
epitope of human epidermal growth factor receptor 2 (HER2). In
addition, multiple partners are using Mersana’s platforms to
advance their ADC pipelines. Mersana Therapeutics was recently
named among the 2021 Top Places to Work in Massachusetts by The
Boston Globe. Mersana routinely posts information that may be
useful to investors on the “Investors and Media” section of its
website at www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024